DRKS00006181招募中未知
Treatment of patients with breast cancer or gastrointestinal cancer and chemotherapy-induced polyneuropathia with whole body vibration (Galileo technology)
Klinik für Tumorbiologie0 个研究点目标入组 50 人开始时间: 2014年7月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •patients with breast cancer or gastrointestinal cancer and Chemotherapy-induced Polyneuropathy
- •rehabilitation planed for at least 3 weeks
- •no further chemotherapy is planed
- •age = 18 years
- •perfomance status: Karnofsky-Index = 80%
- •average of life expectancy of at least 4 months
- •patient is able (i) to understand the being, importance and range of the study and (ii) to give the approval for the participation in the study
- •signed informed consent
排除标准
- •Exclusion criteria
- •diseases which are able to endangering the safety of the patients or which can influence the validity of the study
- •instable bone metastases or osteoporosis
- •myocardial infarction = 6 months, angina pectoris (when the angina pectoris is instable
- •or starts = 3 months)
- •heart disease (NYHA = III)
- •uncontrolled hypertension
- •acute thrombosis
- •severe acute infection
- •acute discopathia, acute tendinopathia
- •acute inflammation of the hinges or of the movement apparatous
- •acute hernia
- •recurring Renal or Bilious colic
- •wounds fresh or being cured badly or ulcera or bone fractures
- •endoprosthesis or insufficient osteosynthetische supply
- •acute bleeding, gastrointestinale hemorrhage = 4 weeks
- •pregnancy
- •greater surgical intervention, difficult trauma = 4 weeks
- •heavy neuropathia (PNP Score = 7)
- •akute rheumatoid arthritis
研究者
相似试验
进行中（未招募）
1 期
Cyclophosphamide chemotherapy for breast cancers harboring TP53 gene mutationsocally advanced breast cancer and metastatic breast cancerEUCTR2016-003459-31-NOHelse Bergen, Haukeland University Hospital190
尚未招募
不适用
A study on the impact of pharmaceutical care on breast cancer patientsCTRI/2020/07/026688Self funded
已完成
2 期
Problem-solving therapy for breast cancer patients undergoing chemotherapy on an outpatient basisBreast cancerJPRN-UMIN000011190Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University100
已完成
不适用
Breast Cancer Care for patients with metastatic diseaseC50C76C77C78C79C80Malignant neoplasm of breastMalignant neoplasm of other and ill-defined sitesSecondary and unspecified malignant neoplasm of lymph nodesSecondary malignant neoplasm of respiratory and digestive organsSecondary malignant neoplasm of other and unspecified sitesMalignant neoplasm, without specification of siteDRKS00013726niversitätsklinikum Würzburg, Frauenklinik und Poliklinik31
进行中（未招募）
不适用
Preoperative treatment of breast cancer with a combination of epirubicin, docetaxel and bevacizumab. A translational trial on molecular markers and functional imaging to predict response early - PROMIXPatients diagnosed with breast cancer who are candidates for preoperative (neoadjuvant) chemotherapy due to localized primary breast cancer including inflammatory breast cancer suitable for primary medical treatment and/or regional lymph node metastases including ipsilateral supraclavicular nodes with breast cancer diagnosis confirmed by histological examination.MedDRA version: 9.1Level: LLTClassification code 10006200Term: Breast cancer stage IIMedDRA version: 9.1Level: LLTClassification code 10006201Term: Breast cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerEUCTR2007-005858-23-SEPROMIX Trial Group200